Skip to main content
GutCited

研究プロセス

477 査読済み研究からの図表

すべて Psyllium Husk Bifidobacterium lactis Fructooligosaccharides (FOS) Lactobacillus plantarum Peppermint Oil Pancreatic Enzymes (Pancrelipase) Curcumin Vitamin A Medium-Chain Triglycerides (MCT Oil) Galactooligosaccharides (GOS) Lactobacillus gasseri Aloe Vera (Inner Leaf Gel) Alpha-Galactosidase Vitamin D L-Glutamine Inulin Ginger Lactase Berberine Omega-3 Fatty Acids (EPA/DHA) Bovine Colostrum Zinc Bifidobacterium bifidum Butyrate (Sodium/Calcium Butyrate) Bacillus coagulans Saccharomyces boulardii Lactobacillus acidophilus N-Acetyl Cysteine (NAC) Bifidobacterium longum
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 25
Figure 25 Chart

Interview coding results for pancreatic exocrine insufficiency symptoms display the relative importance of different symptom domains as rated by patients.

Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) …

Figure 26
Figure 26 Diagram

Final conceptual framework for the PEI patient-reported outcome instrument integrates symptom, impact, and treatment-related domains derived from patient input.

Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) …

Figure 3
Figure 3 Chart

Predictive microbiota signatures for postoperative Crohn's disease recurrence are identified, with specific taxa associated with early endoscopic inflammation at the neoterminal ileum.

Early Postoperative Endoscopic Recurrence in Crohn's Disease Is Characterised by Distinct Microbiota …

Vitamin D is increasingly viewed as an immune modulator capable of directly impacting both innate and adaptive immune responses (Figure 2). Given that almost all immune cells express VDR,2 it is not surprising that vitamin D is closely correlated with imm
Figure 1 Diagram

Vitamin D's multifaceted role as an immune modulator is discussed, noting that nearly all immune cells express the vitamin D receptor and that deficiency is closely correlated with increased susceptibility to immune-mediated diseases.

The Role of Vitamin D in Immune System and Inflammatory Bowel Disease.

Figure 2 Vitamin D impacts the innate and adaptive immunity (By Figdraw (www.figdraw.com)). Notes: In innate immunity, vitamin D inhibit LPS-induced p38 activation and IL-6 and TNF-α production by monocytes, and downregulate TLR-9 expression after stimula
Figure 2 Diagram

Vitamin D impacts on innate and adaptive immunity are illustrated, showing inhibition of LPS-induced p38 activation, suppression of IL-6 and TNF-alpha by monocytes, and downregulation of TLR-9 expression in immune cells.

The Role of Vitamin D in Immune System and Inflammatory Bowel Disease.

Figure 3 Vitamin D influence the development of IBD by directly impacting intestinal immunity, microbiota and the intestinal mucosal barrier. Notes: “↑” = increase/up-regulated; “↓” = decrease/down-regulated. Abbreviations: VDR, vitamin D receptor; ZO-1,
Figure 3 Diagram

Vitamin D's influence on inflammatory bowel disease development is depicted through three interconnected pathways: intestinal immune regulation, microbiota composition, and mucosal barrier integrity.

The Role of Vitamin D in Immune System and Inflammatory Bowel Disease.

To explore the potential role of gut microbiota alterations in BBR’s suppression of HFD-associated CRC development, we performed 16S rRNA
Figure 3 Chart

16S rRNA sequencing of gut microbiota reveals that berberine modulates microbial community composition in high-fat diet-fed mice. Specific bacterial genera associated with colorectal cancer risk were reduced in berberine-treated animals.

Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut …

Figure 4
Figure 4 Chart

Lysophosphatidic acid signaling pathway components are quantified in colonic tissue. Berberine treatment is associated with downregulation of key enzymes in this pathway, suggesting a mechanism for its anti-tumor effects.

Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut …

Figure 5
Figure 5 Chart

Metabolomic profiling of gut contents identifies lysophosphatidic acid and related lipid metabolites altered by berberine supplementation. Reduced levels of pro-tumorigenic lipids correlate with tumor suppression.

Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut …

Figure 6
Figure 6 Chart

Western blot analysis demonstrates changes in protein expression of key signaling molecules in the lysophosphatidic acid pathway following berberine treatment. Reduced phosphorylation of downstream targets indicates pathway inhibition.

Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut …

Figure 7
Figure 7 Chart

Fecal microbiota transplantation experiments confirm the role of gut microbiota in mediating berberine's anti-tumor effects. Mice receiving microbiota from berberine-treated donors showed reduced tumor development.

Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut …

Figure 8
Figure 8 Chart

Correlation analysis between gut microbial abundance and lysophosphatidic acid levels identifies specific bacterial species linked to metabolite production. Berberine's microbiome modulation appears to reduce cancer-promoting metabolites.

Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut …

Figure 9
Figure 9 Chart

Immune cell infiltration in colonic tumors is assessed across treatment groups. Berberine supplementation is associated with increased anti-tumor immune responses and reduced immunosuppressive cell populations.

Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut …

Figure 10
Figure 10 Diagram

A proposed mechanistic model illustrates how berberine inhibits high-fat diet-associated colorectal cancer through gut microbiota remodeling, reduced lysophosphatidic acid production, and modulation of downstream oncogenic signaling.

Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut …

Figure 2
Figure 2 Chart

Total IBS symptom scores decrease significantly in the Bacillus coagulans LBSC group compared to placebo over the treatment period. Both bloating and abdominal pain subscores show improvement.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Figure 3
Figure 3 Chart

Individual IBS symptom domains including bloating, abdominal pain, urgency, and incomplete evacuation are tracked across study visits. Bacillus coagulans supplementation shows benefits across multiple symptom dimensions.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Figure 3. Change in stool consistency from baseline (visit 2/d 1) to end of treatment (visit 4/d 80) in Test-G and Placebo-H. The Bristol stool form scale is used to assess the stool consistency as reported by total number of subjects.
Figure 4 Chart

Stool consistency changes from baseline to end of treatment are assessed using the Bristol Stool Form Scale. The Bacillus coagulans group shows normalization toward type 3-4 stools compared to placebo.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Figure 4. Clustering of multivariate data using principal component analysis analysis of responses for different variables of quality of life from Test-G (G) and Placebo-H (H) arms at end of treatment (visit 04). Variables considered are— abdominal pain,
Figure 5 Chart

Principal component analysis of quality of life responses clusters patients by treatment arm. Bacillus coagulans-treated patients show greater separation from baseline values, indicating improved quality of life dimensions.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Intolerance symptoms are caused by the osmotic effect of lactose on the intestinal lumen and by the fermentation effect of colonic bacteria that produce gases, such as hydrogen, carbon dioxide, and methane (H2, CO2, and CH4), acid and harmful metabolites.
Figure 1 Diagram

Pathophysiology of lactose intolerance illustrating how undigested lactose causes symptoms through osmotic effects in the intestinal lumen and bacterial fermentation producing hydrogen, carbon dioxide, and methane gases.

Lactose intolerance: myths and facts. An update.

Figure 2
Figure 2 Diagram

Diagnostic algorithm or classification scheme for lactose intolerance, distinguishing between primary (genetic), secondary (disease-related), and congenital forms of lactase deficiency.

Lactose intolerance: myths and facts. An update.

Fig. 1. Study protocol.
Figure 1 Flowchart

Study protocol timeline for the trial evaluating continuous consumption of fermented milk containing Bifidobacterium bifidum YIT 10347 in patients with functional gastrointestinal symptoms.

Continuous consumption of fermented milk containing Bifidobacterium bifidum YIT 10347 improves gastrointestinal …

Figure 2
Figure 2 Chart

Gastrointestinal symptom scores over time in patients consuming Bifidobacterium bifidum YIT 10347-containing fermented milk, tracking improvements in dyspepsia and related complaints.

Continuous consumption of fermented milk containing Bifidobacterium bifidum YIT 10347 improves gastrointestinal …

Figure 3
Figure 3 Chart

Psychological symptom assessments in patients with functional gastrointestinal disorders during the probiotic fermented milk intervention period.

Continuous consumption of fermented milk containing Bifidobacterium bifidum YIT 10347 improves gastrointestinal …

Fig. 5. Urinary 8-hydroxy-2’-deoxyguanosine level. Timedependent changes in the urinary 8-OHdG concentration.
Figure 4 Chart

Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) concentration changes over time, reflecting oxidative stress levels during Bifidobacterium bifidum YIT 10347 supplementation.

Continuous consumption of fermented milk containing Bifidobacterium bifidum YIT 10347 improves gastrointestinal …

20ページ中8ページ目